FibroGen Inc (FGEN) - Total Assets
Based on the latest financial reports, FibroGen Inc (FGEN) holds total assets worth $137.01 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
FibroGen Inc - Total Assets Trend (2012–2024)
This chart illustrates how FibroGen Inc's total assets have evolved over time, based on quarterly financial data. Also see FGEN market cap for the company's overall valuation and market capitalisation.
FibroGen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
FibroGen Inc's total assets of $137.01 Million consist of 91.6% current assets and 8.4% non-current assets. Review FGEN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.5% |
| Accounts Receivable | $481.00K | 0.2% |
| Inventory | $3.15 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how FibroGen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for FibroGen Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: FibroGen Inc's current assets represent 91.6% of total assets in 2024, an increase from 19.9% in 2012.
- Cash Position: Cash and equivalents constituted 23.5% of total assets in 2024, up from 14.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 1.5% of total assets.
FibroGen Inc Competitors by Total Assets
Key competitors of FibroGen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
FibroGen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.71 | 1.28 | 4.63 |
| Quick Ratio | 3.60 | 1.16 | 4.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $97.45 Million | $54.00 Million | $591.92 Million |
FibroGen Inc - Advanced Valuation Insights
This section examines the relationship between FibroGen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 53.83 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -49.3% |
| Total Assets | $214.53 Million |
| Market Capitalization | $37.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values FibroGen Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: FibroGen Inc's assets decreased by 49.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for FibroGen Inc (2012–2024)
The table below shows the annual total assets of FibroGen Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $214.53 Million | -49.35% |
| 2023-12-31 | $423.53 Million | -30.58% |
| 2022-12-31 | $610.09 Million | -21.16% |
| 2021-12-31 | $773.82 Million | -6.41% |
| 2020-12-31 | $826.84 Million | -3.56% |
| 2019-12-31 | $857.40 Million | -2.63% |
| 2018-12-31 | $880.60 Million | -2.01% |
| 2017-12-31 | $898.65 Million | +91.38% |
| 2016-12-31 | $469.55 Million | -0.22% |
| 2015-12-31 | $470.57 Million | -2.68% |
| 2014-12-31 | $483.53 Million | +62.83% |
| 2013-12-31 | $296.95 Million | +11.81% |
| 2012-12-31 | $265.59 Million | -- |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more